VIKING THERAPEUTICS INC's ticker is VKTX and the CUSIP is 92686J106. A total of 147 filers reported holding VIKING THERAPEUTICS INC in Q4 2020. The put-call ratio across all filers is 0.76 and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $22,439,422 | -25.0% | 2,026,788 | +9.8% | 0.00% | -25.0% |
| Q2 2023 | $29,930,786 | +108.2% | 1,846,439 | +113.9% | 0.00% | +100.0% |
| Q1 2023 | $14,372,824 | +233604.5% | 863,232 | +31.9% | 0.00% | +100.0% |
| Q4 2022 | $6,150 | -99.7% | 654,306 | +0.2% | 0.00% | – |
| Q3 2022 | $1,776,000 | -10.3% | 653,037 | -4.8% | 0.00% | – |
| Q2 2022 | $1,981,000 | -48.9% | 685,749 | -46.9% | 0.00% | – |
| Q1 2022 | $3,876,000 | -28.7% | 1,292,267 | +9.4% | 0.00% | -100.0% |
| Q4 2021 | $5,435,000 | -27.1% | 1,181,655 | -0.5% | 0.00% | 0.0% |
| Q3 2021 | $7,456,000 | +7.3% | 1,187,322 | +2.3% | 0.00% | 0.0% |
| Q2 2021 | $6,950,000 | +3.2% | 1,160,325 | +9.0% | 0.00% | 0.0% |
| Q1 2021 | $6,733,000 | +22.8% | 1,064,624 | +9.3% | 0.00% | 0.0% |
| Q4 2020 | $5,481,000 | -0.7% | 973,688 | +2.6% | 0.00% | 0.0% |
| Q3 2020 | $5,522,000 | -21.9% | 948,798 | -3.3% | 0.00% | -50.0% |
| Q2 2020 | $7,073,000 | +56.3% | 981,029 | +1.5% | 0.00% | +100.0% |
| Q1 2020 | $4,525,000 | -68.9% | 966,914 | -46.8% | 0.00% | -50.0% |
| Q4 2019 | $14,572,000 | +168.9% | 1,817,030 | +130.6% | 0.00% | +100.0% |
| Q3 2019 | $5,420,000 | -11.8% | 787,851 | +6.4% | 0.00% | 0.0% |
| Q2 2019 | $6,144,000 | -8.2% | 740,301 | +9.9% | 0.00% | -50.0% |
| Q1 2019 | $6,692,000 | -26.4% | 673,320 | -43.4% | 0.00% | +100.0% |
| Q4 2018 | $9,096,000 | +14.7% | 1,189,020 | +161.3% | 0.00% | -50.0% |
| Q3 2018 | $7,927,000 | +110.9% | 455,090 | +14.9% | 0.00% | +100.0% |
| Q2 2018 | $3,758,000 | +267.4% | 396,011 | +69.0% | 0.00% | – |
| Q1 2018 | $1,023,000 | +114.5% | 234,314 | +99.2% | 0.00% | – |
| Q4 2017 | $477,000 | +708.5% | 117,619 | +276.2% | 0.00% | – |
| Q3 2017 | $59,000 | +78.8% | 31,264 | 0.0% | 0.00% | – |
| Q2 2017 | $33,000 | -26.7% | 31,264 | 0.0% | 0.00% | – |
| Q1 2017 | $45,000 | +21.6% | 31,264 | 0.0% | 0.00% | – |
| Q4 2016 | $37,000 | -15.9% | 31,264 | 0.0% | 0.00% | – |
| Q3 2016 | $44,000 | +12.8% | 31,264 | 0.0% | 0.00% | – |
| Q2 2016 | $39,000 | – | 31,264 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| APIS CAPITAL ADVISORS, LLC | 148,000 | $1,638,360 | 2.12% |
| Sio Capital Management, LLC | 595,002 | $6,586,672 | 2.04% |
| 5AM Venture Management, LLC | 585,000 | $6,475,950 | 1.86% |
| Artia Global Partners LP | 383,580 | $4,246,231 | 1.76% |
| Integral Health Asset Management, LLC | 800,000 | $8,856,000 | 1.23% |
| Boxer Capital, LLC | 2,000,000 | $22,140,000 | 1.18% |
| DAFNA Capital Management LLC | 319,655 | $3,538,581 | 1.10% |
| Affinity Asset Advisors, LLC | 332,600 | $3,681,882 | 1.04% |
| MPM BioImpact LLC | 325,000 | $3,597,750 | 0.96% |
| Affinity Asset Advisors, LLC | 300,000 | $3,321,000 | 0.93% |